Facing the future, skin-care research

Biopharmaceutical Senetek will link up with skin care company
Beiersdorf to research a range of compounds for the anti-aging
market. After the conclusion of each evaluation, Beiersdorf can
enter into licenses for the use of the compound in specific markets
worldwide.

Biopharmaceutical Senetek will link up with skin care company Beiersdorf to research a range of compounds.

Under terms of the agreement, after the conclusion of each evaluation, Beiersdorf may enter into licenses for the use of the compound in specific markets worldwide.

Senetek will own and have the right to practice and license all compounds resulting from this collaboration outside of the markets and fields of use that may be licensed to Beiersdorf.

Senetek, that focuses on developing and co-marketing products for the anti-aging markets, currently licenses a number of major pharmaceutical and skin care manufacturers and distributors to use its patented Kinetin compound.

Dr. Klaus-Peter Wittern, corporate vice-president of research & development at Beiersdorf, described the collaboration agreement with Senetek as "a remarkable opportunity for Beiersdorf to further enhance its wide range of innovative high-quality skin care formulations."

Frank Massino, chairman and CEO of Senetek added that the signing of the agreement with Beiersdorf, in combination with the recently established relationship with the Institute of Experimental Botany in the Czech Republic, "validates Senetek's strategy to become a global player based on its core technologies and competencies. We are now properly positioned in Europe with the additions of Andreas Tobler, Chief Operating Officer and Managing Director, Europe and Dr. Brian Clark, Chief Scientist, both of whom were most instrumental in making this important relationship possible."